Skip to content
BioFutureRx

Biopharmaceutical Company · Biologics & Peptides

Advancing Biologic Medicines for a Healthier Future

BioFutureRx advances a deep biologics portfolio — biosimilars, first-in-class antibodies, diagnostics, and delivery platforms — through a strategic development partnership, alongside its own in-house peptide program led by BFRx3711, a novel long-acting GLP-1.

A Biopharmaceutical Company

Biologic medicines, advanced from discovery to market

BioFutureRx is a biopharmaceutical company focused on biologic medicines. Through a strategic development and manufacturing partnership, we advance a broad portfolio of biosimilars, first-in-class antibodies, diagnostics, and delivery platforms — and we engineer our own peptide therapeutics in-house, led by BFRx3711.

Why BioFutureRx

A multi-dimensional portfolio across biologics and peptides

A Deep Biologics Portfolio

Biosimilars, first-in-class and novel antibodies, diagnostics, and delivery platforms — a multi-dimensional portfolio advanced through a strategic development partnership.

First-in-Class Innovation

Novel-target antibody discovery and humanization, led by a clinical-stage candidate in pancreatic cancer, across oncology, immunology, and infectious disease.

Our Own Peptide Program

BFRx3711, a proprietary in-house GLP-1 analog engineered for potential once-monthly dosing — our own asset alongside the biologics portfolio.

Partner with us to advance biologic medicines.

Contact BioFutureRx

Our Network

Part of a connected group.

BioFutureRx works alongside sister companies across pharmaceutical licensing, capital, and marketplace — explore the wider network.